Skip to main content
SpringerLink
Log in

Hyperurikämie und Arthritis urica durch Pyrazinamid

Ihre Beeinflussung durch Urikosurika und Allopurinol

Pyrazinamide-induced hyperuricaemia and arthritis urica

The influence of uricosuric agents and allopurinol

  • Published:
Beiträge zur Klinik und Erforschung der Tuberkulose und der Lungenkrankheiten Aims and scope Submit manuscript

Summary

The treatment with pyrazinamide regularly results in a distinct elevation of uric acid levels in serum. This hyperuricaemia is caused by a significant reduction of renal excretion of uric acid. Long-term therapy with pyrazinamide may lead to typical symptoms of gout — in consequence of constant uric acid retention and tissue storage. These symptoms have been described by others, and could be observed by us as well in three instances.

The pyrazinamide-induced hyperuricaemia can be reduced by uricosuric drugs and allopurinol, according to their respective way of action. The implications of these studies are discussed in detail.

Zusammenfassung

Untersuchungen der Beeinflussung des Harnsäurestoffwechsels durch Pyrazinamid ergaben gesetzmäßig bei jedem Probanden eine deutliche Hyperurikämie. Diese wird durch eine statistisch signifikante Verminderung der renalen Harnsäureausscheidung verursacht. Die Pyrazinamidwirkung beruht nicht auf einer toxischen Nierenschädigung, wie durch intensive Prüfung der Nierenleistung gezeigt werden kann. Nach längerdauernder Pyrazinamidgabe können infolge der dauernden Harnsäureretention und-ablagerung im Gewebe die typischen (Gelenk-)Symptome einer Arthritis urica erscheinen, wie an drei eigenen Beobachtungen gezeigt wird. Die Beeinflußbarkeit dieser Symptome sowie der Pyrazinamidbedingten Harnsäureretention und Hyperurikämie durch Gichtmittel wird dargelegt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. A statement on pyrazinamide. (American Trudeau Society.) Amer. Rev. Tubere.75, 1012 (1957).

    Google Scholar 

  2. Campagna, M.: Observations on the combined use of pyrazinamide and INH in the treatment of pulmonary tuberculosis. Amer. Rev. Tuberc.69, 334 (1954).

    Google Scholar 

  3. Cullen, J. H., L. J. A. Lawrence, andJ. M. Fiore: The occurence of hyperuricemia during pyrazinamide-isoniacid therapy. Amer. Rev. Tuberc.74, 289 (1956).

    Google Scholar 

  4. Davis, B. B., J. B. Field, G. P. Rodnan, andL. H. Kedes: Localization and pyrazinamide inhibition of distal transtubular movement of uric-acid-2-C14 with a modified stop-flow-technique. J. clin. Invest.44, 716 (1965).

    PubMed  Google Scholar 

  5. Folin, O., andW. Denis: J. biol. Chem.13, 469 (1913).

    Google Scholar 

  6. Frey, J.: Endogene und exogene Clearance der Nieren. Med. Klin.62, 547 (1967).

    PubMed  Google Scholar 

  7. Gleason, D. F., J. P. Street, andK.-A. Kahn: Effects of pyrazinamide on serum and urine uric acid. Clin. Res. Proc.4, 246.

  8. Heilmeyer, L., u.Krebs: Biochem. Z.223, 365 (1930).

    Google Scholar 

  9. Jungbluth, H., u.H. Martin: Zur uricosurischen Wirkung eines Sulfoxydanalogen des Phenylbutazons. Chemotherapia3, 487 (1961).

    PubMed  Google Scholar 

  10. Kaplan, K., B. E. Reisberg, andL. Weinstein: Cephaloridine, antimicrobial activity and pharmacological behavior. Amer. J. med. Sci.253, 667 (1967).

    PubMed  Google Scholar 

  11. Klinenberg, J. R.: The effectiveness of the xanthine oxydase inhibitor allopurinol in the treatment of gout. Ann. int. Med.62, 639 (1965).

    PubMed  Google Scholar 

  12. Lee, C. C., E. B. Herr, andR. C. Anderson: Pharmacological and toxicological studies on Cephalothin. Clin. Med.70, Heft 6 (1963).

    Google Scholar 

  13. Schneeweiss, J., andG. W. Poole: Hyperuricaemia due to pyrazinamide. Brit. med. J. II, 830 (1960).

    Google Scholar 

  14. Scott, J. T.: Allopurinol in treatment of gout. Brit. med. J. II, 321 (1966).

    Google Scholar 

  15. Shapiro, M.: Hyperuricemia due to pyrazinamide. Amer. J. Med.23, 596 (1957).

    Article  PubMed  Google Scholar 

  16. Stottmeier, K. D., R. E. Beam, andG. P. Kubica: The absorption and excretion of pyrazinamide. Amer. Rev. resp. Dis.98, 70 (1968).

    PubMed  Google Scholar 

  17. Tuano, S. B., J. L. Brodie, andW. M. M. Kirby: Cephaloridine versus cephalothin: Relation of the kidney to blood level differences after parenteral administration Antimicrob. Agents Chemother.1966, p. 101.

  18. Yeager, R. L., W. G. C. Munrod, andF. I. Dessau: Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Amer. Rev. Tuberc.65, 523 (1952).

    Google Scholar 

  19. Yü, T. F., L. Berger, andA. B. Gutman: Supression of tubular secretion of urate by pyrazinamide in the dog. Proc. Soc. exp. Biol. (N.Y.)107, 905 (1961).

    Google Scholar 

  20. —— ——, andA. B. Gutman: Effect of pyrazinamide and pyrazinoic acid on urate clearance and other discrete renal functions. Proc. Soc. exp. Biol. (N.Y.)96, 264 (1957).

    Google Scholar 

  21. Zins, G. R., andI. M. Weiner: Bidirectional urate transport limited to the proximal tubule in dogs. Amer. J. Physiol.215, 411 (1968).

    PubMed  Google Scholar 

  22. Zöllner, N.: Die Behandlung der Gicht und der Uratnephrolithiasis mit Allopurinol. Verh. Dtsch. Ges. Inn. Med.72, 781 (1966).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sektion Pneumologie des Zentrums der Inneren Medizin der Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany

    R. Kropp & I. Dücker

  2. Städtische Klinik für Lungenkranke Heckeshorn, Berlin

    I. Schütz

Authors
  1. R. Kropp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Dücker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kropp, R., Dücker, I. & Schütz, I. Hyperurikämie und Arthritis urica durch Pyrazinamid. Beitr. Klin. Tuberk. 139, 318–325 (1969). https://doi.org/10.1007/BF02090940

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02090940

Search

Navigation